NSMC Intern Elba Medina creates a crisp VA for the PRAECIS trial.
Also, we have some bonus VAs this time created for NephMadness by our VA editor Divya Bajpai!
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
NSMC Intern Elba Medina creates a crisp VA for the PRAECIS trial.
Also, we have some bonus VAs this time created for NephMadness by our VA editor Divya Bajpai!
Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT Randomized Clinical Trial (Kitt, JAMA 2023)
Any reduction in maternal kidney mass makes a difference during pregnancy in gestational and fetal outcome. (Kidney International 2024)
After CHIP we discussed CHAP. In case you missed it, we have you covered here:
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) June 1, 2022
✳️ Last week's #NephJC in 10 tweets ✳️
Did you miss the latest CHAPter of #NephJC? Join us as we catch you up on the Chronic Hypertension in Pregnancy trial -- the CHAP chat!https://t.co/zdjwgONpt1 pic.twitter.com/4RK5HKulC6